Postoperative bleeding is a common complication following cardiothoracic surgical procedures requiring cardiopulmonary bypass (CPB). Serious bleeding complications requiring the administration of blood products, hemostatic drugs, and even repeat surgery are associated with considerable morbidity, mortality, and resource consumption. Therapy with recombinant activated factor VII (rFVIIa) may be an effective treatment strategy for patients with refractory bleeding. We report the successful use of rFVIIa for the treatment of intractable postoperative bleeding following aortic aneurysm repair in two patients with Marfan syndrome. In both patients, surgical reexploration was avoided, and the patients' clinical status was stabilized after the administration of rFVIIa. In one patient, hemostasis was rapidly achieved within minutes, whereas hemostasis occurred gradually over several hours in the second patient. Including our personal experience with the two cases, the use of rFVIIa has been reported in 20 patients who required CPB for cardiothoracic surgical procedures. Hemostasis was achieved in all patients. In 14 patients (70%), rapid hemostasis was achieved following a single dose of rFVIIa (mean dose, 57 g/kg). In the remaining six patients, gradual hemostasis was achieved after a mean of 3.4 doses (mean cumulative dose, 225 g/kg). Two patients (10%) were believed to have experienced thromboembolic complications after the administration of rFVIIa (one was fatal), and, in another patient, intracoronary thrombosis was suspected but was not confirmed. In patients experiencing postoperative bleeding complications that are refractory to treatment with blood products, hemostatic agents, and/or repeat surgery, the use of rFVIIa may be considered.
P
ostoperative bleeding is one of the most common complications following cardiopulmonary bypass (CPB) in patients undergoing cardiothoracic surgical procedures. Treatment strategies for postoperative bleeding include supportive care with volume resuscitation, the administration of blood products, pharmacologic intervention, and surgical reexploration. Massive hemorrhage requiring surgical reexploration occurs in about 6% of the patients and is associated with considerable morbidity and mortality. 1, 2 Surgical reexploration due to excessive bleeding has been associated with a threefold to fourfold increase in mortality and with multiple morbidities, including renal failure, sepsis, atrial arrhythmias, prolonged mechanical ventilatory support, and increased length of hospital stay. 3 Thus, safe and effective strategies to prevent and treat postoperative bleeding are crucial.
Limitations of Currently Available Pharmacologic Agents
Blood products are often used to correct the anemia that ensues and to promote hemostasis. Fresh-frozen plasma, pooled platelets, and cryoprecipitates replenish clotting factors and other important mediators of the clotting cascade, and are helpful in restoring hemostasis. However, the administration of blood products in this setting has several limitations, including a relatively high rate of trans-fusion-related reactions and adverse effects as well as the potential for disease transmission. Consequently, various pharmacologic agents are used to achieve hemostasis in this setting, including protamine, aprotinin, aminocaproic acid, tranexamic acid, and desmopressin. Protamine effectively reverses the effects of heparin but is associated with several adverse effects, including hypotension, hypersensitivity reactions, and paradoxical anticoagulation with excessive doses. 4 Aprotinin is a serine protease inhibitor with potent antifibrinolytic effects and is often administered prophylactically to prevent bleeding complications in patients having vascular surgery. 5 However, routine prophylaxis is very costly, and aprotinin has been associated with hypersensitivity reactions, particularly with repeated exposure. 5 Aminocaproic acid and tranexamic acid are lysine analogues that bind to the lysine-binding site on plasminogen, inhibiting the conversion of plasminogen to plasmin and effectively inhibiting fibrinolysis. 5 However, when the administration of these drugs is delayed until after open heart surgery, they are of limited benefit compared to prophylactic administration perioperatively. 5 Last, desmopressin increases the release of von Willebrand factor from endothelial cells and increases the circulating levels of factor VIII, leading to more effective hemostasis. [5] [6] [7] However, many patients with severe postoperative bleeding are unresponsive to these drugs.
Mechanism of Action of Recombinant
Activated Factor VII Recombinant activated factor VII (rFVIIa) is a clotting factor that is commonly used to treat bleeding disorders in patients with acquired hemophilia. Because rFVIIa can initiate coagulation independent of factors VIII and IX, it is useful as treatment in patients with hemophilia A or B complicated by high-responding inhibitors. Coagulation is triggered locally at the site of vascular injury as rFVIIa binds with tissue factor, and activates factors IX and X to their active forms (ie, IXa and Xa), ultimately leading to thrombin generation and clot formation. 5, 6 Given its local effects at the site of vascular injury, rFVIIa may have a role in achieving hemostasis in patients experiencing refractory postoperative bleeding complications.
Rationale for Use of rFVIIa
The risk of serious postoperative bleeding complications for patients requiring CPB during cardiothoracic surgical procedures remains high. In these patients, not only is morbidity and mortality increased, but also health-care utilization and costs are higher. 1, 2, 8 Postoperative bleeding in this setting is associated with an increased length of stay, increased use of blood products, and increased use of hemostatic agents to control bleeding. 8 Consequently, postoperative bleeding incurs an average incremental cost of $3,866. In cases of refractory postoperative hemorrhaging requiring surgical reexploration, mortality is more than sevenfold higher (15.4%) and the additional cost is nearly $10,000. 8 Although the prophylactic use of hemostatic agents such as aminocaproic acid, tranexamic acid, and aprotinin are effective in reducing bleeding and the need for the transfusion of blood products, treatment options are limited when serious postoperative bleeding occurs. Since rFVIIa triggers hemostasis locally at the site of the vascular injury, it has a role in the management of patients with intractable bleeding. Its use as a hemostatic agent in nonhemophiliac patients has been described in several cases of severe hemorrhage from disseminated intravascular coagulation, 9 as well as refractory postoperative bleeding following spinal fusion surgery, 10 total hip arthroplasty, 11 major abdominal surgery, 12 pelvic surgery, 13 neurosurgery, 14 and hysterectomy. 15 
Personal Experience
Our experience with rFVIIa in this setup consists of two patients (Table 1) . Both patients had vasculopathies that were associated with Marfan syndrome. One patient presented with a chronic enlarging thoracoabdominal dissecting aneurysm, and the other with an ascending aortic root aneurysm. The first case was considerably more complex as the extent of aortic dissection extended from the distal aortic root to the infrarenal aorta and was complicated by dense adhesions from two prior surgeries. This patient experienced profound hemorrhaging (estimated blood loss, approximately 50 L) postoperatively that was refractory to a massive administration of blood products (approximately 140 U) and hemostatic drugs perioperatively. The use of rFVIIa (120 g/kg) had a dramatic effect on hemostasis. Within minutes of administration, the chest tube output decreased from nearly 1 L/h to Ͻ 100 mL/h (Fig 1, top, A) . The need for blood products was substantially decreased (ie, only 1 U packed RBCs was necessary in the 10 h following administration), hemodynamics were stabilized, and surgical reexploration was avoided. The second patient who had been given rFVIIa following the repair of an aortic root aneurysm using hypothermic circulatory arrest had a more gradual response to the drug, despite repeated doses (Fig 1,  bottom, three doses of rFVIIa were given and therapy with aminocaproic acid was initiated. Surgical reexploration was also avoided in this patient.
Published World Experience
Including the two cases described herein, the use of rFVIIa has been reported in 20 patients with refractory bleeding following procedures requiring CPB or postoperative extracorporeal circulatory support (Table 1) . 16 -28 The patients who received rFVIIa ranged in age from 12 days to 75 years and included 13 male patients and 7 female patients. Six patients had undergone valve replacement and/or repair, 16, 17, 20, 23 four patients had undergone valve replacement with aortic root repair/replacement, 16, 22 two patients had undergone arterial switch operations, 16, 28 two patients had undergone lung transplant operations, 21, 27 and two patients had undergone repair of an aortic aneurysm. 26 Additionally, repair of the atrioventricular canal, 25 placement of a biventricular assist device, 18 coronary artery bypass surgery, 19 and repair of an atrial septal defect were each performed in one patient. 24 Successful hemostasis was achieved in all 20 patients who had received rFVIIa in this setting. Overall, in the 19 patients for whom dosing data were available, the patients received an average of 1.4 doses of rFVIIa, and the mean cumulative dose of rFVIIa was 101 g/kg. In 14 patients (70%), hemostasis was rapid (within the first hour of administration) after a single dose of rFVIIa (mean rFVIIa dose, 57 g/kg). In the remaining patients, hemostasis was more gradual, over several hours, necessitating multiple doses of rFVIIa (mean number of rFVIIa doses, 3.4; mean cumulative dose of rFVIIa, 225 g/kg).
Pitfalls and Risks of rFVIIa Use
The use of rFVIIa is not without its pitfalls. The primary concern when administering rFVIIa for intractable hemorrhage after extracorporeal circulation is promoting a hypercoagulable state. Thrombotic adverse events have been reported 29 in 17 hemophilia patients who received rFVIIa between 1996 and 2001. It has been postulated 30, 31 that bleeding after cardiac surgery is akin to disseminated intravascular coagulation and that activating the hemostatic system with rFVIIa in this setting may increase the risk of thromboembolic events. Indeed, 2 of the 20 patients (10%) who received rFVIIa following extracorporeal circulation experienced thromboembolic events, and such an event was suspected in a third patient. 20, 21, 27 Both patients who developed thromboembolic events hemorrhaged following lung transplantation. 21, 27 One patient was believed to have experienced massive intracardiac and extracorporeal membrane oxygenation circuit thromboses following the administration of both rFVIIa and activated prothrombin complex concentrates; this patient developed cardiac arrest and died. 21 The other patient developed cardiac tamponade requiring surgical intervention to evacuate a large mediastinal thrombosis following rFVIIa administration. 27 In the third patient, cardiac enzyme levels were elevated on postoperative day 1, and coronary thrombosis was suspected, but coronary angiography failed to reveal any coronary pathology. 20 The other concern regarding the use of rFVIIa in nonhemophiliac patients experiencing severe postoperative bleeding complications is cost. The acquisition cost for a 1.2-mg vial of rFVIIa is $1,480. 32 When considering the use of rFVIIa in this setting, the cost of the drug must be weighed against the costs of nondrug therapy, including the administration of blood products and surgery. Given the high costs and adverse outcomes associated with the administration of blood products and surgical reexploration for bleeding complications, the administration of rFVIIa may be a cost-effective treatment strategy in certain instances.
Conclusions
Serious bleeding complications following cardiothoracic surgical procedures requiring extracorporeal circulation remain troublesome. Effective treatment strategies are lacking. Although the successful use of rFVIIa in such instances has been reported in 20 patients to date, its use in this setting has not been studied in a controlled clinical trial. Therefore, the safety and efficacy of rFVIIa for the treatment of bleeding complications following cardiothoracic surgical procedures requiring CPB cannot be fully elucidated until it has been evaluated formally in a clinical trial. Nevertheless, anecdotal reports have suggested that it is effective in achieving rapid hemostasis. For patients with postoperative bleeding that is refractory to blood product administration and hemostatic drugs, therapy with rFVIIa may be considered as a treatment option. Although the dose of rFVIIa is truly unknown, an initial dose of approximately 60 g/kg may be appropriate. If hemostasis is not achieved within 30 to 60 min, consideration may be given to a second dose; however, the costeffectiveness of repeated dosing is questionable given the limited number of experiences reported to date.
